Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us

COVID-19 updates

Picture

COVID-19 Update #138 7/22/2022

7/22/2022

 
COVID-19 Vaccines
 
The CDC’s Advisory Committee on Immunization Practices (ACIP) voted 12-to-0 to recommend Novavax’s COVID-19 vaccine for patients 18 and older on 7/19/2022. The CDC accepted the recommendation and endorsed use of the vaccine on the same day.
 
An analysis of pediatric information from a large Israeli database found the vaccine effectiveness, for the Omicron variant, after two doses of the Pfizer-BioNTech COIVD-19 vaccine to be 51% to prevent infection and 48% to prevent symptomatic COVID-19. An analysis of data on children in Singapore found the vaccine effectiveness, for the Omicron variant, after two doses of the Pfizer-BioNTech COIVD-19 vaccine to be 65.3% to prevent infection and 82.7% to prevent COVID-19 hospitalization.
 
COVID-19 Antivirals
 
A Japanese in-vitro evaluation of COVID-19 treatments found that remdesivir, molnupiravir, and nirmatrelvir retain activity against the BA.2.12.1, BA.4, and BA.5 omicron variants. Bebtelovimab was found to be effective against BA.2.12.1, BA.4, and BA.5. The subvariants are less susceptible to sotrovimab and combination therapy with casirivimab and imdevimab and with tixagevimab and cilgavimab. 


Comments are closed.
    Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker

    Archives

    January 2023
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020

    Categories

    All

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.